Related Experiment Videos
Central serous chorioretinopathy after bone marrow transplantation
1Francis I. Proctor Foundation and Department of Ophthalmogy, University of California at San Francisco, School of Medicine, San Francisco, California 94143, USA.
American Journal of Ophthalmology
|June 1, 2001
Summary
Central serous chorioretinopathy is a rare complication following bone marrow transplantation, potentially causing vision loss. This case highlights its occurrence in a patient with acute myelogenous leukemia, hypertension, and GVHD, emphasizing the need for awareness.
Area of Science:
- Ophthalmology
- Hematology
- Transplantation Medicine
Background:
- Bone marrow transplantation (BMT) is a life-saving procedure for hematologic malignancies.
- Central serous chorioretinopathy (CSC) is a condition characterized by fluid accumulation under the retina.
- CSC is a rare but significant cause of vision impairment post-BMT.
Observation:
- A 46-year-old Filipino male developed multifocal CSC in his left eye four months after BMT for acute myelogenous leukemia.
- The patient had pre-existing systemic hypertension and graft-versus-host disease (GVHD).
- He was concurrently treated with systemic corticosteroids and cyclosporine for GVHD.
Findings:
- The patient's presentation of CSC post-BMT is uncommon.
- Concurrent factors include hypertension, corticosteroid and cyclosporine use, and GVHD.
- These factors may contribute to choroidal vascular compromise, a proposed mechanism for CSC.
Implications:
- This case underscores CSC as a rare etiology of vision loss in BMT recipients.
- Understanding the pathogenesis of BMT-associated CSC may involve compromised choroidal vasculature.
- Further research is warranted to elucidate the relationship between BMT, immunosuppressive therapies, and CSC.